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ABSTRACT The sex steroids, androgens and estrogens,
are major regulators of bone metabolism. However, whether
these hormones act on bone cells through direct or indirect
mechanisms has remained unclear. A nuclear binding assay
recently used to demonstrate estrogen receptors in bone [Erik-
sen, E. F., Colvard, D. S., Berg, N. J., Graham, M. L.,
Mann, K. G., Spelsberg, T. C. & Riggs, B. L. (1988) Science
241, 84-86] was used to identify specific nuclear binding of a
tritiated synthetic androgen, [3H]R1881 (methyltrienolone), in
21 of 25 (84%) human osteoblast-like cell strains and a
concentration of bound steroid receptors of 821 ± 140 (mean
± SEM) molecules per cell nucleus. Binding was saturable and
steroid-specific. Androgen receptor gene expression in osteo-
blasts was confirmed by RNA blot analysis. Relative concen-
trations of androgen and estrogen receptors were compared by
measuring specific nuclear estrogen binding. Nuclear binding
of [3lHestradiol was observed in 27 of 30 (90%) cell strains; the
concentration of bound estradiol receptor was 1537 ± 221 mol-
ecules per cell nucleus. The concentrations of nuclear binding
sites were similar in males and females for both [3H]R1881 and
[3Hlestradiol. We conclude that both androgens and estrogens
act directly on human bone cells through their respective
receptor-mediated mechanisms.
Androgens and estrogens are major regulators of bone
metabolism in males and females, respectively (1). Both
hormones interact with growth hormone in control of the
adolescent growth spurt (2-4). After growth is completed,
androgens and estrogens maintain bone mass in the adult. In
women, menopause causes accelerated bone loss that can be
prevented by estrogen administration (5, 6). Treatment of
postmenopausal women with androgen derivatives, synthetic
anabolic steroids, produces beneficial effects on bone me-
tabolism (7, 8). In males, hypogonadism is associated with
bone loss, which is stabilized by testosterone administration
(9).
Because previous attempts to demonstrate receptors in
bone cells of experimental animals (10, 11) or humans (12)
have been unsuccessful, the prevailing view has been that the
action ofsex steroids on skeletal tissue is mediated indirectly.
Recent data, however, suggest that estrogen has a direct
action. Both specific nuclear binding of estradiol and the
presence of estrogen receptor mRNA were demonstrated in
normal human osteoblast-like cell strains (13) and in rat and
human osteogenic sarcoma cell lines (14). Moreover, biologic
effects ofestrogen treatment in vitro have been demonstrated
on proliferation and differentiation of normal mouse osteo-
blast-like cells (15) and rat osteogenic sarcoma cell lines (16),
on induction of progesterone receptors in human osteoblast-
like cell strains (13), and on induction of gene transcription
for type I procollagen and transforming growth factor P3 in rat
and human osteogenic sarcoma cell lines (14).
We have investigated the possibility that bone cells contain
androgen receptors as well as estrogen receptors. These
studies were carried out with cultured human osteoblast-like
cells by using a sensitive, nuclear binding assay for functional
sex steroid receptors (17, 18). In addition, a cDNA probe for
the human androgen receptor (19) was used to determine
whether human osteoblasts contained androgen receptor
mRNA.
METHODS
Cell Culture. Human bone cells were cultured from fresh
samples of trabecular bone obtained during orthopedic pro-
cedures, by a procedure modified from that developed by
Robey and Termine (20). These cultured cells had the typical
characteristics of the osteoblast phenotype (13, 21). In brief,
residual fibrous tissue was carefully dissected from the bone
samples, which were then washed and minced in phosphate-
buffered saline and digested with crude bacterial collagenase
(GIBCO) at 1 mg/ml in Dulbecco's modified Eagle's medium
(DMEM, GIBCO) for 2 hr at 370C in a shaking water bath.
These fragments were then cultured in a phenol red-free
medium (GIBCO) approximately equivalent to a Ca2+-free
1:1 (vol/vol) mixture of Ham's F-12 and DMEM supple-
mented with 10% heat-inactivated fetal bovine serum and
penicillin/streptomycin. Steroid receptor assays were rou-
tinely performed after the second passage of cells in 175-cm2
culture flasks (20-30 population doublings). Two to 3 months
of culture were required to obtain the 4 million cells needed
for each assay in replicate.
In experiments to assess nuclear binding of radiolabeled
steroids, the medium was replaced for 48 hr by the same
medium containing 20% fetal bovine serum and 2 mM Ca2'.
Twenty-four hours before receptor assay, the medium was
changed to serum-free medium containing 2 mM Ca2 .
Nuclear Binding Assay. The specific nuclear binding of
tritiated steroids in these cells was measured by a nuclear
binding assay as described in detail previously and modified
for tissue culture cells (13, 17, 18). In brief, human osteoblast-
like cells at confluence were removed by trypsinization and
suspended in MCDB-202 medium (Irvine Scientific). Repli-
cate aliquots of the cell suspension (0.5-1 x 106 cells per
replicate)wereincubated with [17a-methyl-3H]R1881 (methyl-
trienolone, a potent synthetic androgen) (DuPont) or [2, 4, 6,
7(n)-3H]estradiol (DuPont) at a final concentration of 10 nM
with or without a 100-fold excess of the respective nonradi-
olabeled steroid for estimation of nonspecific and total
binding for 1 hr at 370C. When sufficient cells were available,
quadruplicate assays were done. After the 1-hr incubation,
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the cells were collected by centrifugation, washed in MCDB-
202 medium, and suspended in homogenization buffer [50
mM Tris, pH 7.5/10%o (vol/vol) glycerol/10 mM KCl/0.1%
Triton X-100/0.1% bovine serum albumin]. The cells were
homogenized in a Teflon pestle/glass homogenizer (Thomas
type A) and the homogenate was layered over a cushion of 1.4
M sucrose in homogenization buffer and centrifuged for 20
min at 7000 X g.
Each nuclear pellet was extracted with ethanol and the
radioactivity was determined by liquid scintillation spectrom-
etry in a LS-5801 liquid scintillation counter (Beckman). The
DNA in each replicate was quantitated by a micro version
(17) of the diphenylamine assay of Burton (22) with calf
thymus DNA (Calbiochem) treated similarly as a standard.
Control experiments indicated that a minimum of 1 jug of
DNA per replicate was required for a reliable diphenylamine
assay.
Calculations. The specific nuclear steroid binding was
determined by subtracting the average of the replicate assays
for the total binding of [3H]steroid (expressed in disintegra-
tions per minute per microgram of DNA) minus the corre-
sponding average of the replicate assays for the nonspecific
binding. Since a negative calculated value of specific nuclear
binding essentially indicates no specific binding, negative
values were reset to zero. For calculation of molecules per
cell nucleus, a value of 6 ,ug of DNA per 106 cells was used
(23).
RNA Extraction and Northern Blot Hybridization. Total
RNA was extracted from single cell strains with guanidinium
thiocyanate (24), enriched for mRNA by oligo(dT)-cellulose
chromatography (25), and separated electrophoretically in a
1% agarose gel. The RNA was transferred to nylon and hybrid-
ized overnight at 430C with human androgen receptor cDNA
labeled with [a-32P]dCTP by means of a multiprime kit
(Amersham). The cDNA probe was a 713-base-pair HindIll-
EcoRP fragment ofARHFL1 (19). The blot was washed twice
at 65°C with 15 mM NaCl/1.5 mM sodium citrate, pH 7/0.1%
sodium dodecyl sulfate for 15 min and analyzed by autorad-
iography.
RESULTS
Specific Nuclear Androgen Binding in Human Osteoblast-
like Cells. Specific nuclear binding of the tritiated synthetic
androgen [3H]R1881 (methyltrienolone) was found in 11 of 12
(92%) osteoblast-like cell strains derived from male patients
and in 10 of 13 (77%) cell strains from female patients (Fig.
1 Left). For all osteoblast-like cell strains combined, andro-
gen receptor concentration was 821 ± 140 (mean ± SEM)
molecules per cell nucleus. The nuclear androgen receptor
concentration in the male strains was 628 ± 124 molecules per
nucleus and ranged from 0 to 1550 molecules per nucleus. The
nuclear androgen receptor concentration in the female strains
was 998 ± 233 molecules per nucleus and ranged from 0 to
2750 molecules per nucleus. There was, however, no statis-
tically significant difference between the two means (0.5 > P
> 0.1, Student's t test).
Measurements of estrogen receptors in osteoblast-like cell
strains were extended beyond a previous report (13) in which
the mean concentration in seven strains from females was
reported to be 1615 ± 410 molecules per cell nucleus. The
nuclear estradiol receptor concentration for all 30 cell strains,
including the original 7 strains, was 1537 ± 221. The mean
concentration for the 15 female strains was 1854 ± 306 and
that for the 15 male strains was 1220 ± 297 (Fig. 1 Right).
Although the mean estrogen receptor concentration in female
strains was higher, the difference was not statistically signif-
icant (0.5 > P > 0.1, Student's t test).
Saturation of Nuclear Androgen Binding in Human Osteo-













FIG. 1. Nuclear androgen and estrogen receptor binding in
normal human osteoblast-like cells. Specific nuclear receptor binding
in human osteoblast-like cells was determined as described in
Methods. Dots represent the mean calculated number of molecules
per cell nucleus for each strain. (Left) Specific nuclear binding of
[3H]R1881 (methyltrienolone, an androgen analog) in 12 strains from
normal men and 13 strains from normal women. (Right) Specific
nuclear [3H]estradiol binding in 15 strains from men and 15 strains
from women was determined. The mean receptor concentrations are
indicated by the horizontal lines.
observed above was due to classical androgen receptors,
saturation of receptor binding and steroid-specific binding
were demonstrated. For saturation of nuclear steroid recep-
tor binding, osteoblast-like cells from single strains, or from
several pooled strains, were incubated with various concen-
trations of [3H]R1881 and processed for nuclear binding.
Data points on nuclear androgen receptor binding (Fig. 2)
each represent a composite offour separate experiments and
demonstrate saturable binding of [3H]R1881. The shape ofthe
curve for specific nuclear binding in all four experiments was
essentially identical; thus, the SEM bars in Fig. 2 reflect the
fact that saturation was achieved at approximately 2300,
2800, 1500, and 600 molecules per nucleus, respectively.
Steroid Specificity of Nuclear Androgen Binding in Human
Osteoblast-like Cells. The specificity of nuclear steroid bind-
ing was tested to further verify the presence of specific
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FIG. 2. Saturation of nuclear [3H]R1881 binding in normal human
osteoblast-like cells. Osteoblast-like cells at confluence were
trypsinized, washed with MCDB-202 medium, incubated with 0.5-10
nM [3H]R1881 alone or with 100-fold excess unlabeled R1881, and
processed for specific nuclear binding. Data points present the means
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When total [3H]R1881 nuclear binding was measured with a
variety of homologous or nonhomologous steroids as com-
petitors, only nonradiolabeled R1881 competed significantly
with [3H]R1881 for nuclear binding (Fig. 3). Diethylstilbestrol
(DES, a synthetic estrogen), as well as dexamethasone
(DEX) and triamcinolone acetonide (TAC, a synthetic glu-
cocorticoid), competed only slightly with [3H]R1881 thus
demonstrating specific androgen receptor binding. Triamcin-
olone acetonide was used in several experiments to eliminate
[3H]R1881 binding to progesterone and glucocorticoid recep-
tors (26). Competition by triamcinolone acetonide ranged
from 7% to 23% with a mean competition of 17%. Since the
limited cell numbers available for study precluded using
triamcinolone acetonide for each replicate assay point, the
concentration of androgen receptors given in Figs. 1 and 2
may be slightly overestimated.
Detection of Androgen Receptor Gene Expression in Normal
Osteoblast-like Cells. The results of RNA analysis by North-
ern blot hybridization support the conclusion that androgen
receptor is expressed in human osteoblast-like cells from
normal males (Fig. 4). A single band at -10 kilobases was
observed with mRNA from human osteoblast-like cells and
from an androgen receptor-positive tissue, rat ventral pros-
tate (lane 2), when probed with a cDNA for the human
androgen receptor (18). mRNA from hen spleen, a tissue
devoid of androgen receptor binding activity, did not contain
the 10-kilobase species (lane 3). Expression of androgen
receptor mRNA was similar in three strains of human
osteoblasts tested.
DISCUSSION
Our data provide strong evidence for the presence of andro-
gen receptors in normal human bone cells of the osteoblast
lineage. Specific nuclear binding of [3H]R1881 (methyl-
trienolone, a potent synthetic androgen) was found in the
large majority of cell strains studied. The nuclear binding
assay employed for these studies provides added specificity
because it measures only functional steroid receptors. Func-
tional receptors are defined as those that not only bind the
steroid but also become activated and bind to nuclear
acceptor sites (18, 27). This event correlates with the biologic









FIG. 3. Steroid specificity ofnuclear [3H]R1881 binding in human
osteoblast-like cells. Human osteoblast-like cells at confluence were
harvested by trypsinization, washed with MCDB-202 medium, and
incubated with 10 nM [3H]R1881 alone or with 100-fold excess
unlabeled R1881, diethylstilbestrol (DES), dexamethasone (DEX),
triamcinolone acetonide (TAC), or R5020 (promegestrone, a proges-
terone analogue). Nuclearcbindictofnear[Hned bindinginthe assay
described in Methods. Data presented is expressed as the mean
percent of binding relative to the nuclear binding in the absence of
competing steroid for each competing steroid from six separate






FIG. 4. Northern blot analysis of androgen receptor gene expres-
sion in normal human osteoblast-like cells. mRNA (10 ,ug per lane)
isolated from normal human osteoblast-like cells and control tissues
was analyzed by blot hybridization with a cDNA to the human
androgen receptor (19). Lanes 1, normal male osteoblast-like cells;
2, rat ventral prostate; 3, adult hen spleen. Positions of size markers
are indicated at left (kb, kilobases).
saturable and steroid-specific as is characteristic of steroid
target tissues (27). Expression of the androgen receptor gene
in these cells was confirmed by RNA blot analysis. Thus,
human bone cells contain receptors for both androgen and
estrogen.
Failure of earlier studies to detect sex-steroid receptors in
bone cells likely resulted from methodological problems.
Earlier studies were performed before it was recognized that
assays using dextran-coated charcoal require the addition of
molybdate and/or protease inhibitors for stabilization of
low-abundance receptors and to protect against proteolytic
degradation (28). Moreover, previous studies utilized mixed
populations of bone cells, whereas the present study was
made on nearly homogeneous populations of cells that
exhibited the complete osteoblast phenotype (21).
The androgen receptor concentration of 821 ± 140 mole-
cules per cell nucleus found in the cultured human bone cells
was comparable to the concentration of 1270 ± 483 molecules
per cell nucleus found in 16 samples of normal human
prostate (that is, tissue adjacent to prostatic cancer) and 1611
+ 970 molecules per cell nucleus found in benign hyper-
trophic prostate obtained at the time of prostatic surgery
(unpublished data). Nuclear androgen receptor binding in
excess of 500 molecules per nucleus in prostatic cancer tissue
correlates significantly with increased survival of the patient
and with the duration of response to hormonal therapy (29).
The concentration of androgen receptors found in normal
human osteoblast-like cells should, therefore, be sufficient
for biological activity.
The average concentration of estrogen receptors in the
cultured human osteoblast-like cells was about twice the
average concentration of androgen receptors. Studies in
animal systems have shown that concentrations of 500-1000
estrogen receptors per cell nucleus are needed to induce
transcriptional activity (18, 30, 31).
Whether the observed concentrations in cultured cell
strains are lower than concentrations in bone cells in vivo is
unknown. It is possible, however, that prolonged culture of
these cells in the absence of sex steroids influenced receptor
concentration or encouraged the clonal selection of cells
deficient in sex-steroid receptors.
Even though the predominant circulating sex steroid in
men is testosterone and the predominant circulating sex
steroids in premenopausal women are estradiol and estrone,
androgens and estrogens circulate in both sexes. Our findings
that bone cells contain both androgen and estrogen receptors
and that their concentrations in cells from male and female
donors were similar for each receptor suggest that both sex
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steroids contribute to the maintenance of bone mass in both
sexes. This might be particularly true in postmenopausal
women, whose serum estrogens fall to low levels but whose
serum testosterone declines only slightly (32).
In summary, our data suggest that both androgens and
estrogens act directly on human bone cells through their
respective receptor-mediated mechanisms. These findings
underscore the importance of sex steroids in bone biology.
Both androgen and estrogen deficiency may have important
implications in the causation of osteoporosis, an enormously
important public health problem.
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